Fundamentals of ctDNA

Jeanne Tie, MBChB, FRACP, MD, Peter MacCallum Cancer Centre and The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, reflects on the use of circulating tumor DNA (ctDNA) approaches in oncology. Prof. Tie defines ctDNA and highlights the types of assays available, as well as potential pitfalls that clinicians may face when ordering and interpreting tests such as false negatives. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.